Background
==========

Renal transplant is considered as the most effective therapeutic treatment for end-stage renal disease \[[@b1-medscimonit-25-9138],[@b2-medscimonit-25-9138]\]. Compared with dialysis treatments, renal transplant allows patients to have a better quality of life and longer survival \[[@b3-medscimonit-25-9138]\]. However, various complications, such as acute rejection (AR), chronic allograft dysfunction, and immunosuppressive agent-related nephrotoxicity, still strictly limit its wide application \[[@b4-medscimonit-25-9138]\]. Graft loss, increased risk of chronic allograft dysfunction, and poor long-term outcomes are some of the clinical concerns related to AR \[[@b5-medscimonit-25-9138],[@b6-medscimonit-25-9138]\]. Therefore, understanding the pathogenesis of AR is imperative for improving long-term and short-term prognosis in patients.

The TGF-β family of polypeptides includes 3 TGF-β isoforms, activins, nodal, and bone morphogenetic proteins (BMPs), and growth and differentiation factors (GDFs) \[[@b7-medscimonit-25-9138]\]. In contrast to the large number of TGF-β ligands, SMAD proteins, as fewer receptors and downstream intracellular effectors, mediate the transduction of intracellular signaling. In mammals, 7 type I receptors and 5 type II receptors were identified and were shown to form a heteromeric complex of type I and type II transmembrane receptors \[[@b8-medscimonit-25-9138]--[@b10-medscimonit-25-9138]\].

The TGF-β signaling pathway is widely involved in regulation of cellular responses, including cell growth and differentiation, apoptosis, homeostasis, and many other cellular functions \[[@b11-medscimonit-25-9138],[@b12-medscimonit-25-9138]\]. TGF-β has various regulatory functions which range from specifying tissue pattern formation as morphogens during embryonic development to maintaining physiological homeostasis as cytokines in adult organisms. It is now widely accepted that TGF-β is a bifunctional regulator. TGF-β is a suppressor of early-stage tumors and has also been observed to promote tumor growth and progression by inducing epithelial-to-mesenchymal transition (EMT) \[[@b13-medscimonit-25-9138]--[@b15-medscimonit-25-9138]\]. TGF-β has immune-suppressive functions in several diseases \[[@b16-medscimonit-25-9138],[@b17-medscimonit-25-9138]\]. Moreover, TGF-β, as an immune-regulatory cytokine, plays a crucial role in the development, homeostasis, and tolerance of T cells \[[@b18-medscimonit-25-9138]\]. The immune response meditated by T cells is the main cause of AR, but the association of the TGF-β signaling pathway with AR is yet to be fully determined.

A genome-wide association study (GWAS) identified genetic variants and their association with human diseases, which enables analysis of millions of single-nucleotide polymorphisms (SNPs) in the genome. GWAS may be applied to identify novel molecules and pathways involved in acute rejection and to predict transplant outcomes \[[@b19-medscimonit-25-9138]\]. The aim of this retrospective, single-center study was to investigate the correlation between SNPs in TGF-β signaling pathway-related genes and the susceptibility to AR by use of target sequencing (TS) based on next-generation sequencing (NGS) at our center.

Material and Methods
====================

Study design and population
---------------------------

This work is a retrospective, single-center, cohort study, which was carried out to explore the influence of SNPs in TGFB signaling pathway-related genes (*TGF-*β*1, TGF-*β*2, TGF-*β*3, TGF-*β*R1, TGF-*β*R2, TGF-*β*R3, SMAD2, SMAD3, SMAD4*) on the risk of AR in renal transplant recipients. The Ethics Committee of the First Affiliated Hospital of Nanjing Medical University approved the protocols followed in this study (2016-SR-029). Written informed consents were obtained from all transplant recipients. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Recipients in this study were strictly limited to living-related transplantation of donors to lineal or collateral relatives not beyond the third degree of kinship or transplantation of kidney donors after cardiac death, from 2011 to 2015.

This study included 200 renal transplant recipients who received renal transplant between 1 February 2011 and 1 December 2015 at the kidney transplant center of the Nanjing Medical University First Affiliated Hospital, as detailed in our previous study \[[@b20-medscimonit-25-9138]\]. Briefly, we enrolled adult patients who underwent single-kidney transplantation, with or without AR period confirmed by biopsy. Medical records of enrolled patients were meticulously extracted and reviewed by 2 clinicians (ZJ Wang and RY Tan).

Clinical data on age, sex, height, AR incidence, delayed graft function (DGF), and immunosuppressive protocols were also extracted independently by 2 authors (Ming Zheng and Jiajun Zhou). AR after kidney transplantation was diagnosed by 2 independent pathologists through application of histological examination of hematoxylin-eosin staining and immunohistological staining based on the Banff 15 criteria \[[@b21-medscimonit-25-9138]\]. AR scores were classified by the degree of interstitial infiltration and intimal arteritis according to the type/grade of AR based on the Banff 15 criteria.

Ethics approval and consent to participate
------------------------------------------

The Ethics Committee of the First Affiliated Hospital of Nanjing Medical University approved the protocols followed in this study (2016-SR-029). Written informed consent was obtained from all transplant recipients. Peripheral blood samples (2 mL) from each recipient were collected. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Recipients in this study were strictly limited to living-related transplantation of donors to lineal or collateral relatives not beyond the third degree of kinship or transplantation of kidney donors after cardiac death, from 2011 to 2015.

Immunosuppressive protocols
---------------------------

All recipients in our center underwent routine immunosuppressive protocols that included 3 or 4 drugs. Briefly, the basic protocol consisted of tacrolimus taken at an initial dosage of 0.2 mg/kg/day (*q12h*), with mycophenolate mofetil (MMF) at an initial dosage of 0.75--1.0 g/day (*q12h*) 24--48 h after transplantation, and prednisone, combined with or without sirolimus at an initial dosage of 1 mg/day (*qd*). The combined usage of sirolimus or not depended on drug concentrations, immunoreaction, and clinical symptoms of recipients. These dosages were later calibrated according to the serum creatinine levels and drug concentrations. As determined by the tolerance and response of recipients, tacrolimus could later be changed to cyclosporin A during follow-up. For patients who had AR episodes, methylprednisolone was administered intravenously at a dosage of 200 mg/day for 3--5 days. Detailed information on the immunosuppressive agents used in our center can be found in our previous study \[[@b22-medscimonit-25-9138]\].

Sample collection, preparation, and TS
--------------------------------------

Peripheral blood samples (2 mL) from each recipient were collected. After DNA extraction, the concentration and purity of genomic DNA (gDNA) was quantitatively analyzed and gene integrity was accessed through application of agarose gel electrophoresis. A pool containing upstream and downstream oligonucleotides was selected as gDNA hybrids specific to target regions of interest. Then, the gDNA was fragmented and the adapter-ligated DNA was amplified through selective, limited-cycle polymerase chain reaction. The captured libraries were denatured and loaded into an Illumina cBot instrument as per the manufacturer's instructions. Then, sequencing data based on the human reference sequence UCSC hg19 assembly (NCBI build 37.2) was analyzed using the Genome Analysis Tool Kit, Picard software, and dbSNP 132. During this procedure, putative somatic variant cells with 2 separate programs -- MuTect 1.1.5 and VarScan 2.3.6 -- were also observed.

Statistical analysis
--------------------

Data are presented as mean±standard deviation (SD) except when stated otherwise. We explored minor allele frequency (MAF) and Hardy-Weinberg equilibrium (HWE) by using R packages genetics (genetics: Population Genetics, R package version 1.3.8.1.). Linkage disequilibrium (LD) blocks were analyzed by using Haploview version 4.2 (Broad Institute, Cambridge, MA, USA). The general linear model (GLM) was applied to examine the influence of clinical variables on AR. We used R package SNPassoc (SNPassoc: SNPs-based whole-genome association studies, R package version 1.9-2.) to perform 5 sirolimus-adjusted multiple inheritance models, including codominant model 1 (major allele homozygotes *vs*. heterozygotes), codominant model 2 (major allele homozygotes *vs*. minor allele homozygotes), dominant model (major allele homozygotes *vs*. minor allele homozygotes plus heterozygotes), recessive model (major allele homozygotes plus heterozygotes *vs*. minor allele homozygotes), over-dominant model (heterozygotes *vs*. major allele homozygotes plus minor allele homozygotes), and log-additive model (major allele homozygotes *vs*. heterozygotes *vs*. minor allele homozygotes). The Bonferroni correction method (the α value for each comparison equal to the fixed α value divided by the total number of comparisons) was performed to avoid the inflation of p-values from multiple comparisons \[[@b23-medscimonit-25-9138]\]. Chi-square analysis and exact chi-square analysis of variance were used to compare Banff score values when considering 2 or 3 genotypes. All data were analyzed by SPSS 13.0 software (SPSS, Inc., Chicago, IL, USA). *P*\<0.05 was considered statistically significant.

Results
=======

Baseline characteristics of study participants
----------------------------------------------

[Table 1](#t1-medscimonit-25-9138){ref-type="table"} presents the baseline clinical characteristics of the renal transplant recipients: age, sex, weight, and incidence of DGF. A total of 200 recipients (124 men and 76 women) who underwent first ABO-matched single-kidney transplantation were included in this study. Of these, 69 recipients (42 men and 27 women) had experienced at least 1 AR episode. None of the 200 recipients had detected panel reactive antibody (PRA) before transplantation. Comprehensive and detailed information on recipients and other clinical information can be found in our previous study \[[@b20-medscimonit-25-9138]\].

Association analysis between tagger SNPs and AR
-----------------------------------------------

A total of 188 SNPs on TGF-β signaling pathway genes were detected by target sequencing. Detailed information on chromosome, position, function, and details are presented in [Supplementary Table 1](#s2-medscimonit-25-9138){ref-type="supplementary-material"}. Among these, 47 novel SNPs were reported for the first time. SNPs with a MAF \>0.05 were identified as normal frequency, whereas MAF \<0.05 were considered as rare frequency SNPs. The analysis of HWE highlighted 38 SNPs with MAF \>0.05 and HWE \>0.05 ([Supplementary Table 2](#s3-medscimonit-25-9138){ref-type="supplementary-material"}). During the study, Haploview version 4.2 was used to further analyze haplotypes by evaluating LD block and haplotype among 38 SNPs. After the adjustment of LD analysis, 31 tagger SNPs with 10 blocks (Block1: rs11466512-rs2228048, Block2: rs2241716-rs2241717-rs1800470, Block3: rs1065080-rs2289261-rs2289259-rs7179893, Block4: rs2289790-rs2289791, Block5: rs3917187-rs3917201, Block6: rs284878-rs2038931, Block7: rs1805113-rs1750641, Block8: rs10783002-rs2306888-rs11165376-rs12124904, Block9: rs1805110-rs1805109, Block10: rs11568753-rs11568778-rs334354) were included for further research ([Figure 1](#f1-medscimonit-25-9138){ref-type="fig"}, [Supplementary Figure 1](#s1-medscimonit-25-9138){ref-type="supplementary-material"}, [Supplementary Table 3](#s4-medscimonit-25-9138){ref-type="supplementary-material"}). However, no significant correlation was observed between the haplotypes and AR.

GLM analysis was undertaken to investigate the influence of the distribution of various clinical variables on the occurrence of AR. The use of sirolimus or not was found to be significantly related with the distribution of AR with a *P* value of 0.015 after the analysis of Pillai's Trace, Wilks' Lambda, Hotelling's Trace, and Roy's Largest Root ([Supplementary Table 4](#s5-medscimonit-25-9138){ref-type="supplementary-material"}). Other clinical variables, including age, sex, weight, and DGF showed no significant relation with AR ([Supplementary Table 4](#s5-medscimonit-25-9138){ref-type="supplementary-material"}). Thereafter, 5 models adjusted by the use of sirolimus were used to analyze the effect of tagger SNPs on AR by a corrected statistically significant P value according to Bonferroni correction method (corrected-P=0.01).The tagger SNP rs1131243 on *TGF-*β *Receptor 3* (*TGFBR3*) gene exhibited significant correlation with the occurrence of AR in 4 of the 5 models as *P*=0.00037 in codominant model (OR1=3.71, 95% CI1: 1.82--7.58, OR2=5.41, 95% CI2: 1.14--25.75), *P*=7.79E-05 in dominant model (OR=3.9, 95% CI: 1.97--7.72), *P*=0.11 in recessive model (OR=3.57, 95% CI: 0.77--16.54), *P*=0.00073 in over-dominant model (OR=3.31, 95% CI: 1.65--6.65), and *P*=0.00011 in log-additive model (OR=3.04, 95% CI: 1.7--5.43) ([Table 2](#t2-medscimonit-25-9138){ref-type="table"}). No corrected statistical significance was observed in the other 30 SNPs ([Supplementary Table 5](#s6-medscimonit-25-9138){ref-type="supplementary-material"}).

Effect of SNPs on histological examination outcome
--------------------------------------------------

Of the 200 recipients included in this study, 69 were diagnosed as having AR by allograft biopsy. The degree of AR was determined based on histological examination and according to Banff 15 criteria. Of these 69 recipients, 38 were classified as borderline, 24 were classified as Banff IA, 2 were classified as Banff I B and Banff IIB (1 recipient each), and 5 were classified as Banff IIA. No significant correlation was observed between the type of rs1131243 and the degree of AR (df=8, χ^2^=8.386, *P*=0.3967, [Table 3A](#t3a-medscimonit-25-9138){ref-type="table"}). As the presence of endarteritis confirmed in biopsy is the criterion that distinguishes between I and II degree of AR by Banff 15, the level of AR was divided into 2 groups. The degree of borderline, IA, and IB were regarded as a single group and the degree of II and more than II was regarded as the other group. We found that recipients who carried the rs1131243 T variant were more likely to have endarteritis and a higher level of AR. However, no significant difference was identified between rs1131243 and the 2 groups with a *P* value of 0.055 (df=2, exact χ^2^=4.86, [Table 3B](#t3b-medscimonit-25-9138){ref-type="table"}).

Discussion
==========

In this study, TS assay was performed based on NGS technology to identify the associations of SNPs of the TGF-β signaling pathway with AR following kidney transplantation. Mutations on rs1131243 of *TGF-*β*R3* gene were observed for the first time and found to be significantly correlated with increasing risk of AR in renal transplant recipients.

Changes in *TGF-*β*R1* and *TGF-*β*R2* gene can lead to growth inhibition in cells by TGF-β signaling pathway mediation \[[@b24-medscimonit-25-9138]\]. Kim et al. reported that a synonymous SNP -- rs2228048 of the *TGF-*β*R2* gene -- is associated with acute rejection in Korean renal transplant recipients \[[@b25-medscimonit-25-9138]\]. In our study, we also detected SNP rs2228048 in Chinese recipients. However, the SNP rs2228048 showed a *P* value of 0.8146 based on the HWE analysis in our cohort, which indicated that equilibrium had been achieved. Variations of SNPs among human populations may be the reason for differences in these results.

TGF-βR3, also known as betaglycan, is the most abundant of the TGF-β receptors \[[@b26-medscimonit-25-9138]\]. It has a high affinity for both homodimeric and heterodimer TGF-β1 and TGF-β2 \[[@b27-medscimonit-25-9138]\]. Recent genetic studies of TGF-βR3 have reported its role in several diseases. According to Kao et al., SNP rs6696224 of *TGF-*β*R3* gene was significantly associated with heart failure and preserved ejection fraction in the Cardiovascular Health Study (CHS) \[[@b28-medscimonit-25-9138]\]. The rs1192415 of *TGF-*β*R3* gene has been observed to be associated with primary open angle glaucoma among various human populations \[[@b29-medscimonit-25-9138],[@b30-medscimonit-25-9138]\]. In the white population, a SNP rs1805110 on the *TGF-*β*R3* gene was found to be associated with Behçet's disease and idiopathic intermediate uveitis \[[@b31-medscimonit-25-9138]\].

The present results show that rs1131243, an SNP on the *TGF-*β*R3* gene located in 3′-untranslated region sequences, is significantly correlated with the occurrence of post-transplantation AR episodes in first-time renal transplant patients. Recipients carrying the rs1131243 T variant appear to have a higher risk of AR after kidney transplantation. Kumar et al. stated that the *TGF-*β*R3* gene in acute rejection recipients was significantly upregulated among non-rejection recipients after intestinal transplantation in children based on quantitative real-time PCR \[[@b32-medscimonit-25-9138]\]. TGF-βR3, which has no known signaling domain, is reported to regulate the TGF-β signaling pathway by enhancing the binding of TGF-β ligands to TGF-β type II receptors by binding TGF-β and presenting it to TGF-βR2 \[[@b33-medscimonit-25-9138],[@b34-medscimonit-25-9138]\]. Variants of *TGF-*β*R3* can lead to the activation of diverse downstream substrates and regulatory proteins, influencing the transcription of various target genes that function in differentiation, proliferation, and activation of many types of immune cells \[[@b12-medscimonit-25-9138]\]. Our research indicates that the rs1131243 variant of 3′-UTR on the *TGF-*β*R3* gene alters the function of TGF-βR3, thereby affecting the occurrence of AR.

This study did not observe any statistically significant difference between the genotype of rs1131243 and the level of AR in the 69 patients confirmed by histological examination. The results of the present study indicate that rs1131243 T variant causes a higher risk of AR but does not influence the severity. Since the presence of endarteritis confirmed by biopsy is the dividing criteria between Banff I and II degree of AR based on Banff 15, the AR patients were categorized into 2 groups. We observed that recipients who carried the rs1131243 T variant were more likely to have endarteritis and a higher level of AR. However, after analysis using the exact chi-square test, no statistically significant difference was observed with a P value of 0.055. The relatively low number of AR recipients may have contributed to the border line P value. More recipients confirmed by biopsy should be included in further research to verify the result.

This study has certain limitations. This was a single-center study of 200 patients from eastern China who received renal transplantation and it may not have comprehensively covered the influence of SNPs in AR. Some SNPs which occur in a specific cohort may have been inadvertently ignored in this study. Also, SNPs with a MAF \<0.05 in the cohort of our center were not sufficiently included in this study and thus may have led us to miss certain crucial findings. Negative results of other TGF-β and SMAD genes in this study might not be adequate to rule out the function of related genes and downstream proteins in the occurrence of AR.

Conclusions
===========

We found that an SNP -- rs1131243 on the *TGF-*β*R3* gene -- is significantly related to the risk of AR in renal transplant recipients but does not influence the severity of AR.

Supplementary Data
==================

###### 

Linkage disequilibrium analysis of tagger SNPs.

###### 

Detailed information of 188 SNPs on TGF-β signaling pathway genes.

  Chromosome   Position    Reference allele   Alternation allele   Gene name   Function   avsnp144      Gene detail
  ------------ ----------- ------------------ -------------------- ----------- ---------- ------------- -------------------------------------------------------------------------------------------------------------------------------------------------
  chr18        45368162    C                  T                    SMAD2       UTR3       .             NM_001003652: c.\*36G\>A;NM_001135937: c.\*36G\>A;NM_005901: c.\*36G\>A
  chr18        45368395    C                  T                    SMAD2       Intronic   .             .
  chr18        45368457    C                  T                    SMAD2       Intronic   rs79502327    .
  chr18        45371509    C                  T                    SMAD2       Intronic   rs1787186     .
  chr18        45371546    T                  G                    SMAD2       Intronic   .             .
  chr18        45371623    T                  C                    SMAD2       Intronic   rs781465847   .
  chr18        45371791    C                  T                    SMAD2       Exonic     rs1804712     SMAD2: NM_001135937: exon9: c.G1110A: p.Q370Q,SMAD2: NM_001003652: exon10: c.G1200A: p.Q400Q,SMAD2: NM_005901: exon10: c.G1200A: p.Q400Q
  chr18        45374824    C                  T                    SMAD2       Intronic   rs150503321   .
  chr18        45375054    T                  C                    SMAD2       Exonic     rs2282656     SMAD2: NM_001135937: exon7: c.A699G: p.L233L,SMAD2: NM_001003652: exon8: c.A789G: p.L263L,SMAD2: NM_005901: exon8: c.A789G: p.L263L
  chr18        45375138    C                  T                    SMAD2       Intronic   rs368276908   .
  chr18        45377682    T                  C                    SMAD2       Exonic     rs146872557   SMAD2: NM_001135937: exon6: c.A657G: p.L219L,SMAD2: NM_001003652: exon7: c.A747G: p.L249L,SMAD2: NM_005901: exon7: c.A747G: p.L249L
  chr18        45377752    G                  A                    SMAD2       Intronic   rs187015964   .
  chr18        45391368    T                  C                    SMAD2       Intronic   .             .
  chr18        45394653    G                  A                    SMAD2       Intronic   rs72661146    .
  chr18        45394662    C                  A                    SMAD2       Intronic   rs72661145    .
  chr18        45394919    T                  C                    SMAD2       Intronic   rs1787177     .
  chr18        45395548    T                  C                    SMAD2       Intronic   .             .
  chr18        45422862    T                  C                    SMAD2       Intronic   .             .
  chr18        45423208    A                  G                    SMAD2       Intronic   .             .
  chr15        67358470    C                  T                    SMAD3       UTR5       rs36221703    NM_005902: c.-23C\>T
  chr15        67358478    G                  A                    SMAD3       UTR5       rs1061427     NM_005902: c.-15G\>A
  chr15        67358558    G                  A                    SMAD3       Exonic     rs187952791   SMAD3: NM_005902: exon1: c.G66A: p.E22E
  chr15        67391319    C                  T                    SMAD3       Intronic   rs760598093   .
  chr15        67391336    C                  T                    SMAD3       Intronic   rs184408275   .
  chr15        67391497    C                  A                    SMAD3       Intronic   rs1866319     .
  chr15        67430223    T                  C                    SMAD3       Intronic   rs1866318     .
  chr15        67430466    T                  C                    SMAD3       Intronic   .             .
  chr15        67430492    A                  G                    SMAD3       Intronic   .             .
  chr15        67430552    T                  C                    SMAD3       Intronic   rs12914140    .
  chr15        67457335    A                  G                    SMAD3       Exonic     rs1065080     SMAD3: NM_001145103: exon2: c.A177G: p.L59L,SMAD3: NM_005902: exon2: c.A309G: p.L103L
  chr15        67457485    G                  C                    SMAD3       Intronic   rs2289261     .
  chr15        67457647    C                  T                    SMAD3       Exonic     rs145380987   SMAD3: NM_001145102: exon3: c.C142T: p.L48L,SMAD3: NM_001145103: exon3: c.C325T: p.L109L,SMAD3: NM_005902: exon3: c.C457T: p.L153L
  chr15        67457807    C                  T                    SMAD3       Intronic   rs2289260     .
  chr15        67457815    C                  T                    SMAD3       Intronic   .             .
  chr15        67457840    G                  A                    SMAD3       Intronic   rs56336520    .
  chr15        67457850    G                  A                    SMAD3       Intronic   rs2289259     .
  chr15        67458930    C                  T                    SMAD3       Intronic   rs7179840     .
  chr15        67459013    C                  T                    SMAD3       Intronic   rs7179893     .
  chr15        67459307    A                  T                    SMAD3       Intronic   .             .
  chr15        67462729    G                  A                    SMAD3       Intronic   rs3743341     .
  chr15        67473847    C                  T                    SMAD3       Intronic   rs549919159   .
  chr15        67476952    G                  T                    SMAD3       Intronic   rs2289791     .
  chr15        67476970    T                  C                    SMAD3       Intronic   rs2289790     .
  chr15        67476986    C                  T                    SMAD3       Intronic   rs545596731   .
  chr15        67479198    C                  T                    SMAD3       Intronic   rs191278238   .
  chr15        67479524    G                  A                    SMAD3       Intronic   .             .
  chr15        67479591    G                  A                    SMAD3       Intronic   .             .
  chr15        67482696    A                  G                    SMAD3       Intronic   rs28410524    .
  chr18        48573689    A                  G                    SMAD4       Intronic   rs77389132    .
  chr18        48573718    T                  A                    SMAD4       Intronic   .             .
  chr18        48575389    T                  C                    SMAD4       Intronic   rs2276163     .
  chr18        48575544    T                  C                    SMAD4       Intronic   .             .
  chr18        48577782    G                  C                    SMAD4       Intronic   rs7229678     .
  chr18        48577894    G                  A                    SMAD4       Intronic   rs118185031   .
  chr18        48584863    T                  G                    SMAD4       Intronic   rs556951898   .
  chr18        48586175    A                  G                    SMAD4       Intronic   .             .
  chr18        48586184    A                  G                    SMAD4       Intronic   rs948589      .
  chr18        48586328    T                  A                    SMAD4       Intronic   rs758408803   .
  chr18        48586344    C                  T                    SMAD4       Intronic   rs948588      .
  chr18        48593617    T                  C                    SMAD4       Intronic   rs139741673   .
  chr19        41836947    G                  C                    T/GFB1      UTR3       .             NM_000660: c.\*10C\>G
  chr19        41837123    C                  T                    T/GFB1      Splicing   rs199982059   NM_000660: exon8: c.1015-8G\>A
  chr19        41837997    C                  T                    T/GFB1      Intronic   rs570977266   .
  chr19        41838174    C                  T                    T/GFB1      Exonic     rs190566789   T/GFB1: NM_000660: exon6: c.G873A: p.K291K
  chr19        41838206    G                  A                    T/GFB1      Intronic   rs8179181     .
  chr19        41838287    C                  T                    T/GFB1      Intronic   rs13306709    .
  chr19        41847736    T                  C                    T/GFB1      Intronic   rs542695848   .
  chr19        41847933    A                  T                    T/GFB1      Exonic     rs569594975   T/GFB1: NM_000660: exon5: c.T715A: p.F239I
  chr19        41847956    G                  A                    T/GFB1      Intronic   rs763345073   .
  chr19        41848038    C                  T                    T/GFB1      Intronic   rs200134934   .
  chr19        41848075    C                  T                    T/GFB1      Exonic     .             T/GFB1: NM_000660: exon4: c.G712A: p.G238R
  chr19        41850710    C                  T                    T/GFB1      Exonic     rs766221068   T/GFB1: NM_000660: exon3: c.G576A: p.S192S
  chr19        41850742    G                  A                    T/GFB1      Exonic     rs753852676   T/GFB1: NM_000660: exon3: c.C544T: p.L182F
  chr19        41850921    C                  T                    T/GFB1      Intronic   rs531039494   .
  chr19        41854052    C                  A                    T/GFB1      Intronic   rs2241717     .
  chr19        41854086    C                  T                    T/GFB1      Intronic   rs2241716     .
  chr19        41854400    C                  T                    T/GFB1      Intronic   rs376729112   .
  chr19        41854452    C                  T                    T/GFB1      Intronic   .             .
  chr19        41854477    A                  C                    T/GFB1      Intronic   .             .
  chr19        41854534    T                  A                    T/GFB1      Intronic   rs8108632     .
  chr19        41858838    T                  A                    T/GFB1      Exonic     .             T/GFB1: NM_000660: exon1: c.A112T: p.M38L
  chr19        41858867    G                  A                    T/GFB1      Exonic     .             T/GFB1: NM_000660: exon1: c.C83T: p.A28V
  chr19        41858921    G                  A                    T/GFB1      Exonic     rs1800470     T/GFB1: NM_000660: exon1: c.C29T: p.P10L
  chr19        41859047    A                  C                    T/GFB1      UTR5       .             NM_000660: c.-98T\>G
  chr1         218607317   G                  A                    T/GFB2      Intronic   .             .
  chr1         218607796   C                  T                    T/GFB2      Splicing   .             NM_001135599: exon5: c.838+6C\>T;NM_003238: exon4: c.754+6C\>T
  chr1         218607817   G                  T                    T/GFB2      Intronic   rs748386982   .
  chr1         218607922   A                  G                    T/GFB2      Intronic   .             .
  chr1         218610691   G                  T                    T/GFB2      Exonic     .             T/GFB2: NM_003238: exon6: c.G939T: p.V313V,T/GFB2: NM_001135599: exon7: c.G1023T: p.V341V
  chr14        76425446    G                  T                    T/GFB3      UTR3       rs188123116   NM_003239: c.\*84C\>A
  chr14        76427103    A                  G                    T/GFB3      Intronic   rs115411167   .
  chr14        76427473    C                  G                    T/GFB3      Intronic   .             .
  chr14        76429555    C                  T                    T/GFB3      Intronic   rs3917201     .
  chr14        76429868    A                  G                    T/GFB3      Intronic   rs3917200     .
  chr14        76431886    T                  A                    T/GFB3      Intronic   rs200111860   .
  chr14        76432136    T                  C                    T/GFB3      Intronic   rs3917187     .
  chr14        76437409    C                  A                    T/GFB3      Intronic   rs200181092   .
  chr14        76437431    G                  A                    T/GFB3      Intronic   rs752520633   .
  chr14        76437614    A                  G                    T/GFB3      Intronic   rs3917176     .
  chr14        76437638    C                  T                    T/GFB3      Intronic   rs201310311   .
  chr14        76437817    C                  T                    T/GFB3      Intronic   rs554067491   .
  chr14        76438137    C                  G                    T/GFB3      Intronic   rs537980685   .
  chr14        76446750    G                  A                    T/GFB3      Intronic   .             .
  chr14        76446782    G                  C                    T/GFB3      Intronic   .             .
  chr14        76446943    C                  T                    T/GFB3      Exonic     rs778214495   T/GFB3: NM_003239: exon1: c.G294A: p.S98S
  chr14        76447049    G                  T                    T/GFB3      Exonic     rs757664433   T/GFB3: NM_003239: exon1: c.C188A: p.T63N
  chr9         101890227   C                  T                    T/GFBR1     Intronic   rs11568753    .
  chr9         101890294   A                  G                    T/GFBR1     Intronic   rs189740990   .
  chr9         101890980   A                  G                    T/GFBR1     Intronic   rs7041311     .
  chr9         101891294   A                  G                    T/GFBR1     Exonic     .             T/GFBR1: NM_001130916: exon2: c.A255G: p.V85V,T/GFBR1: NM_004612: exon2: c.A255G: p.V85V
  chr9         101891447   G                  C                    T/GFBR1     Intronic   rs56402414    .
  chr9         101891478   C                  T                    T/GFBR1     Intronic   .             .
  chr9         101900392   C                  G                    T/GFBR1     Intronic   .             .
  chr9         101900410   A                  G                    T/GFBR1     Intronic   rs11568778    .
  chr9         101907072   T                  C                    T/GFBR1     Exonic     rs192662552   T/GFBR1: NM_001130916: exon5: c.T801C: p.N267N,T/GFBR1: NM_004612: exon6: c.T1032C: p.N344N
  chr9         101907222   C                  T                    T/GFBR1     Intronic   rs56251429    .
  chr9         101908915   G                  A                    T/GFBR1     Intronic   rs334354      .
  chr3         30648248    C                  G                    T/GFBR2     Utr5       rs2306856     NM_001024847: c.-128C\>G;NM_003242: c.-128C\>G
  chr3         30648538    C                  G                    T/GFBR2     Intronic   .             .
  chr3         30648636    T                  G                    T/GFBR2     Intronic   .             .
  chr3         30664732    A                  C                    T/GFBR2     Exonic     rs200111443   T/GFBR2: NM_001024847: exon2: c.A136C: p.S46R
  chr3         30664864    T                  C                    T/GFBR2     Intronic   rs117998227   .
  chr3         30686107    A                  C                    T/GFBR2     Intronic   .             .
  chr3         30686264    C                  T                    T/GFBR2     Exonic     rs769570752   T/GFBR2: NM_003242: exon2: c.C120T: p.D40D,T/GFBR2: NM_001024847: exon3: c.C195T: p.D65D
  chr3         30686414    A                  G                    T/GFBR2     Splicing   rs1155705     NM_001024847: exon3: c.338+7A\>G;NM_003242: exon2: c.263+7A\>G
  chr3         30691692    C                  A                    T/GFBR2     Intronic   .             .
  chr3         30713126    T                  A                    T/GFBR2     Splicing   rs11466512    NM_001024847: exon5: c.530-4T\>A;NM_003242: exon4: c.455-4T\>A
  chr3         30713246    G                  A                    T/GFBR2     Exonic     rs56105708    T/GFBR2: NM_003242: exon4: c.G571A: p.V191I,T/GFBR2: NM_001024847: exon5: c.G646A: p.V216I
  chr3         30713292    C                  T                    T/GFBR2     Exonic     rs150022335   T/GFBR2: NM_003242: exon4: c.C617T: p.T206M,T/GFBR2: NM_001024847: exon5: c.C692T: p.T231M
  chr3         30713314    C                  T                    T/GFBR2     Exonic     rs200332401   T/GFBR2: NM_003242: exon4: c.C639T: p.S213S,T/GFBR2: NM_001024847: exon5: c.C714T: p.S238S
  chr3         30713619    C                  T                    T/GFBR2     Exonic     rs34833812    T/GFBR2: NM_003242: exon4: c.C944T: p.T315M,T/GFBR2: NM_001024847: exon5: c.C1019T: p.T340M
  chr3         30713842    C                  T                    T/GFBR2     Exonic     rs2228048     T/GFBR2: NM_003242: exon4: c.C1167T: p.N389N,T/GFBR2: NM_001024847: exon5: c.C1242T: p.N414N
  chr3         30713945    T                  C                    T/GFBR2     Intronic   rs45515293    .
  chr3         30730096    G                  A                    T/GFBR2     Intronic   .             .
  chr3         30732821    C                  A                    T/GFBR2     Intronic   rs2276767     .
  chr3         30733100    G                  A                    T/GFBR2     UTR3       .             NM_001024847: c.\*9G\>A;NM_003242: c.\*9G\>A
  chr3         30733102    G                  A                    T/GFBR2     UTR3       .             NM_001024847: c.\*11G\>A;NM_003242: c.\*11G\>A
  chr1         92149139    C                  T                    T/GFBR3     UTR3       rs1805115     NM_001195683: c.\*157G\>A;NM_001195684: c.\*157G\>A;NM_003243: c.\*157G\>A
  chr1         92149277    C                  T                    T/GFBR3     UTR3       rs1131243     NM_001195683: c.\*19G\>A;NM_001195684: c.\*19G\>A;NM_003243: c.\*19G\>A
  chr1         92149503    A                  T                    T/GFBR3     Intronic   .             .
  chr1         92161307    C                  T                    T/GFBR3     Exonic     rs141883791   T/GFBR3: NM_001195683: exon16: c.G2356A: p.V786M,T/GFBR3: NM_003243: exon16: c.G2359A: p.V787M,T/GFBR3: NM_001195684: exon17: c.G2356A: p.V786M
  chr1         92161515    T                  A                    T/GFBR3     Intronic   rs2253316     .
  chr1         92163682    C                  G                    T/GFBR3     Exonic     rs17882828    T/GFBR3: NM_001195683: exon15: c.G2290C: p.G764R,T/GFBR3: NM_003243: exon15: c.G2293C: p.G765R,T/GFBR3: NM_001195684: exon16: c.G2290C: p.G764R
  chr1         92163786    G                  T                    T/GFBR3     Intronic   rs2296621     .
  chr1         92174260    A                  G                    T/GFBR3     Exonic     rs284878      T/GFBR3: NM_001195683: exon14: c.T2244C: p.T748T,T/GFBR3: NM_003243: exon14: c.T2247C: p.T749T,T/GFBR3: NM_001195684: exon15: c.T2244C: p.T748T
  chr1         92174383    A                  G                    T/GFBR3     Intronic   rs78893665    .
  chr1         92174415    G                  A                    T/GFBR3     Intronic   rs2038931     .
  chr1         92177740    C                  T                    T/GFBR3     Intronic   rs528216123   .
  chr1         92177938    A                  G                    T/GFBR3     Exonic     rs1805113     T/GFBR3: NM_001195683: exon13: c.T2025C: p.F675F,T/GFBR3: NM_003243: exon13: c.T2028C: p.F676F,T/GFBR3: NM_001195684: exon14: c.T2025C: p.F675F
  chr1         92178172    T                  C                    T/GFBR3     Intronic   rs573785401   .
  chr1         92178259    C                  T                    T/GFBR3     Intronic   rs1750641     .
  chr1         92178260    A                  G                    T/GFBR3     Intronic   rs1613413     .
  chr1         92181670    C                  A                    T/GFBR3     Intronic   rs2029354     .
  chr1         92181678    T                  G                    T/GFBR3     Intronic   rs2029355     .
  chr1         92181746    T                  C                    T/GFBR3     Intronic   rs140473734   .
  chr1         92184673    G                  A                    T/GFBR3     Intronic   rs4658260     .
  chr1         92184744    C                  T                    T/GFBR3     Intronic   rs4658261     .
  chr1         92184814    G                  T                    T/GFBR3     Intronic   rs7524066     .
  chr1         92185059    A                  T                    T/GFBR3     Intronic   rs61748118    .
  chr1         92185134    A                  C                    T/GFBR3     Intronic   rs186586693   .
  chr1         92185136    C                  T                    T/GFBR3     Intronic   rs577773521   .
  chr1         92185185    T                  C                    T/GFBR3     Intronic   rs2279455     .
  chr1         92185657    C                  T                    T/GFBR3     Exonic     rs1805112     T/GFBR3: NM_001195683: exon9: c.G1203A: p.P401P,T/GFBR3: NM_003243: exon9: c.G1206A: p.P402P,T/GFBR3: NM_001195684: exon10: c.G1203A: p.P401P
  chr1         92185715    A                  G                    T/GFBR3     Exonic     .             T/GFBR3: NM_001195683: exon9: c.T1145C: p.L382P,T/GFBR3: NM_003243: exon9: c.T1148C: p.L383P,T/GFBR3: NM_001195684: exon10: c.T1145C: p.L382P
  chr1         92185881    G                  A                    T/GFBR3     Intronic   .             .
  chr1         92195221    C                  T                    T/GFBR3     Intronic   .             .
  chr1         92195229    C                  T                    T/GFBR3     Intronic   .             .
  chr1         92195555    T                  G                    T/GFBR3     Intronic   .             .
  chr1         92195601    G                  A                    T/GFBR3     Intronic   rs10783002    .
  chr1         92195652    T                  C                    T/GFBR3     Intronic   rs11466584    .
  chr1         92200376    G                  A                    T/GFBR3     Exonic     rs376528004   T/GFBR3: NM_001195683: exon5: c.C525T: p.T175T,T/GFBR3: NM_003243: exon5: c.C525T: p.T175T,T/GFBR3: NM_001195684: exon6: c.C525T: p.T175T
  chr1         92200382    T                  C                    T/GFBR3     Exonic     rs2306888     T/GFBR3: NM_001195683: exon5: c.A519G: p.S173S,T/GFBR3: NM_003243: exon5: c.A519G: p.S173S,T/GFBR3: NM_001195684: exon6: c.A519G: p.S173S
  chr1         92200389    A                  G                    T/GFBR3     Exonic     rs186259544   T/GFBR3: NM_001195683: exon5: c.T512C: p.V171A,T/GFBR3: NM_003243: exon5: c.T512C: p.V171A,T/GFBR3: NM_001195684: exon6: c.T512C: p.V171A
  chr1         92200513    A                  C                    T/GFBR3     Exonic     rs759218481   T/GFBR3: NM_001195683: exon5: c.T388G: p.S130A,T/GFBR3: NM_003243: exon5: c.T388G: p.S130A,T/GFBR3: NM_001195684: exon6: c.T388G: p.S130A
  chr1         92200520    G                  C                    T/GFBR3     Splicing   rs138007142   NM_001195683: exon6: c.385-4C\>G;NM_001195684: exon7: c.385-4C\>G;NM_003243: exon6: c.385-4C\>G
  chr1         92200593    A                  G                    T/GFBR3     Intronic   rs11165376    .
  chr1         92200597    G                  A                    T/GFBR3     Intronic   rs12124904    .
  chr1         92200601    T                  G                    T/GFBR3     Intronic   .             .
  chr1         92200627    T                  C                    T/GFBR3     Intronic   rs10874913    .
  chr1         92200634    C                  T                    T/GFBR3     Intronic   rs11165377    .
  chr1         92224067    C                  T                    T/GFBR3     Intronic   rs3738441     .
  chr1         92224347    G                  A                    T/GFBR3     Intronic   rs11165441    .
  chr1         92262874    T                  C                    T/GFBR3     Exonic     rs2810904     T/GFBR3: NM_001195683: exon3: c.A216G: p.A72A,T/GFBR3: NM_003243: exon3: c.A216G: p.A72A,T/GFBR3: NM_001195684: exon4: c.A216G: p.A72A
  chr1         92263079    G                  A                    T/GFBR3     Intronic   rs17881268    .
  chr1         92266656    A                  G                    T/GFBR3     Intronic   rs72716444    .
  chr1         92266836    C                  T                    T/GFBR3     Intronic   rs12123363    .
  chr1         92327045    G                  A                    T/GFBR3     Exonic     rs1805110     T/GFBR3: NM_001195683: exon2: c.C44T: p.S15F,T/GFBR3: NM_003243: exon2: c.C44T: p.S15F,T/GFBR3: NM_001195684: exon3: c.C44T: p.S15F
               92327126    C                  T                    T/GFBR3     UTR5       rs1805109     NM_001195683: c.-38G\>A;NM_001195684: c.-38G\>A;NM_003243: c.-38G\>A

###### 

HWE and MAF analysis of 188 SNPs.

  SNP               Position    HWE        MAF     REF: ALT
  ----------------- ----------- ---------- ------- ----------
  rs10874913        92200627    7.24E-58   0.45    C: T
  rs1866319         67391497    2.86E-31   0.11    C: A
  rs7179840         67458930    4.08E-22   0.15    C: T
  rs1866318         67430223    8.54E-09   0.02    C: T
  rs2253316         92161515    2.00E-04   0.028   T: A
  rs1787186         45371509    6.00E-04   0.49    T: C
  rs2279455         92185185    6.00E-04   0.092   T: C
  rs2276163         48575389    0.0053     0.043   T: C
  rs8108632         41854534    0.013      0.14    T: A
  rs7041311         101890980   0.015      0.007   A: G
  rs2029354         92181670    0.10       0.018   C: A
  rs2029355         92181678    0.10       0.018   T: G
  rs4658261         92184744    0.10       0.018   C: T
  rs11165377        92200634    0.11       0.07    C: T
  rs2810904         92262874    0.14       0.20    C: T
  rs45515293        30713945    0.22       0.025   T: C
  rs1805115         92149139    0.26       0.028   C: T
  rs2038931         92174415    0.29       0.4     G: A
  rs2289261         67457485    0.29       0.39    G: C
  rs1131243         92149277    0.43       0.16    C: T
  rs1805110         92327045    0.31       0.39    G: A
  rs1805109         92327126    0.31       0.39    C: T
  rs12124904        92200597    0.31       0.48    G: A
  rs1613413         92178260    0.33       0.25    G: A
  rs2241716         41854086    0.36       0.28    C: T
  rs11165376        92200593    0.38       0.49    G: A
  rs10783002        92195601    0.43       0.45    G: A
  rs2289791         67476952    0.47       0.48    G: T
  rs11165441        92224347    0.49       0.22    G: A
  rs11466512        30713126    0.50       0.38    T: A
  rs2276767         30732821    0.50       0.11    C: A
  rs7179893         67459013    0.56       0.33    C: T
  rs2289790         67476970    0.57       0.47    T: C
  rs2296621         92163786    0.60       0.043   G: T
  rs2241717         41854052    0.60       0.36    C: A
  rs1155705         30686414    0.63       0.33    G: A
  rs1061427         67358478    0.67       0.20    G: A
  rs3917201         76429555    0.68       0.48    C: T
  rs11568753        101890227   0.73       0.41    C: T
  rs1805113         92177938    0.73       0.10    A: G
  rs3917187         76432136    0.77       0.47    C: T
  rs334354          101908915   0.77       0.44    G: A
  rs1750641         92178259    0.79       0.37    T: C
  rs7229678         48577782    0.81       0.46    G: C
  rs2228048         30713842    0.81       0.25    C: T
  rs2289259         67457850    0.88       0.25    G: A
  rs3738441         92224067    0.90       0.3     T: C
  rs2306856         30648248    1          0.007   C: G
  Chr3: 30648538    30648538    1          0.003   C: G
  Chr3: 30648636    30648636    1          0.003   T: G
  rs200111443       30664732    1          0.005   A: C
  rs117998227       30664864    1          0.007   T: C
  Chr3: 30686107    30686107    1          0.003   A: C
  rs769570752       30686264    1          0.003   C: T
  Chr3: 30691692    30691692    1          0.003   C: A
  rs56105708        30713246    1          0.022   G: A
  rs150022335       30713292    1          0.003   C: T
  rs200332401       30713314    1          0.003   C: T
  rs34833812        30713619    1          0.022   C: T
  Chr3: 30730096    30730096    1          0.003   G: A
  Chr3: 30733100    30733100    1          0.003   G: A
  Chr3: 30733102    30733102    1          0.003   G: A
  Chr19: 41836947   41836947    1          0.003   G: C
  rs199982059       41837123    1          0.013   C: T
  rs570977266       41837997    1          0.003   C: T
  rs190566789       41838174    1          0.013   C: T
  rs8179181         41838206    1          0.003   G: A
  rs13306709        41838287    1          0.003   C: T
  rs542695848       41847736    1          0.003   T: C
  rs569594975       41847933    1          0.003   A: T
  rs763345073       41847956    1          0.003   G: A
  rs200134934       41848038    1          0.005   C: T
  Chr19: 41848075   41848075    1          0.003   C: T
  rs766221068       41850710    1          0.003   C: T
  rs753852676       41850742    1          0.003   G: A
  rs531039494       41850921    1          0.003   C: T
  rs376729112       41854400    1          0.003   C: T
  Chr19: 41854452   41854452    1          0.003   C: T
  Chr19: 41854477   41854477    1          0.003   A: C
  Chr19: 41858838   41858838    1          0.003   T: A
  Chr19: 41858867   41858867    1          0.003   G: A
  rs1800470         41858921    1          0.46    G: A
  Chr19: 41859047   41859047    1          0.003   A: C
  Chr18: 45368162   45368162    1          0.003   C: T
  Chr18: 45368395   45368395    1          0.003   C: T
  rs79502327        45368457    1          0.005   C: T
  Chr18: 45371546   45371546    1          0.003   T: G
  rs781465847       45371623    1          0.003   T: C
  rs1804712         45371791    1          0.003   C: T
  rs150503321       45374824    1          0.003   C: T
  rs2282656         45375054    1          0.003   T: C
  rs368276908       45375138    1          0.003   C: T
  rs146872557       45377682    1          0.003   T: C
  rs187015964       45377752    1          0.003   G: A
  Chr18: 45391368   45391368    1          0.003   T: C
  rs72661146        45394653    1          0.02    G: A
  rs72661145        45394662    1          0.02    C: A
  rs1787177         45394919    1          0.015   T: C
  Chr18: 45395548   45395548    1          0.003   T: C
  Chr18: 45422862   45422862    1          0.003   T: C
  Chr18: 45423208   45423208    1          0.003   A: G
  rs77389132        48573689    1          0.02    A: G
  Chr18: 48573718   48573718    1          0.003   T: A
  Chr18: 48575544   48575544    1          0.003   T: C
  rs118185031       48577894    1          0.015   G: A
  rs556951898       48584863    1          0.003   T: G
  Chr18: 48586175   48586175    1          0.003   A: G
  rs948589          48586184    1          0.003   A: G
  rs758408803       48586328    1          0.003   T: A
  rs948588          48586344    1          0.043   C: T
  rs139741673       48593617    1          0.03    T: C
  rs36221703        67358470    1          0.025   C: T
  rs187952791       67358558    1          0.02    G: A
  rs760598093       67391319    1          0.003   C: T
  rs184408275       67391336    1          0.01    C: T
  Chr15: 67430466   67430466    1          0.003   T: C
  Chr15: 67430492   67430492    1          0.003   A: G
  rs12914140        67430552    1          0.043   T: C
  rs1065080         67457335    1          0.195   G: A
  rs145380987       67457647    1          0.003   C: T
  rs2289260         67457807    1          0.003   C: T
  Chr15: 67457815   67457815    1          0.003   C: T
  rs56336520        67457840    1          0.005   G: A
  Chr15: 67459307   67459307    1          0.003   A: T
  rs3743341         67462729    1          0.003   G: A
  rs549919159       67473847    1          0.007   C: T
  rs545596731       67476986    1          0.013   C: T
  rs191278238       67479198    1          0.005   C: T
  Chr15: 67479524   67479524    1          0.003   G: A
  Chr15: 67479591   67479591    1          0.003   G: A
  rs28410524        67482696    1          0.01    A: G
  rs188123116       76425446    1          0.005   G: T
  rs115411167       76427103    1          0.005   A: G
  Chr14: 76427473   76427473    1          0.003   C: G
  rs3917200         76429868    1          0.033   A: G
  rs200111860       76431886    1          0.003   T: A
  rs200181092       76437409    1          0.003   C: A
  rs752520633       76437431    1          0.003   G: A
  rs3917176         76437614    1          0.018   A: G
  rs201310311       76437638    1          0.005   C: T
  rs554067491       76437817    1          0.007   C: T
  rs537980685       76438137    1          0.003   C: G
  Chr14: 76446750   76446750    1          0.003   G: A
  Chr14: 76446782   76446782    1          0.003   G: C
  rs778214495       76446943    1          0.003   C: T
  rs757664433       76447049    1          0.003   G: T
  Chr1: 92149503    92149503    1          0.003   A: T
  rs141883791       92161307    1          0.005   C: T
  rs17882828        92163682    1          0.037   C: G
  rs284878          92174260    1          0.23    G: A
  rs78893665        92174383    1          0.01    A: G
  rs528216123       92177740    1          0.003   C: T
  rs573785401       92178172    1          0.007   T: C
  rs140473734       92181746    1          0.003   T: C
  rs4658260         92184673    1          0.003   G: A
  rs7524066         92184814    1          0.092   G: T
  rs61748118        92185059    1          0.03    A: T
  rs186586693       92185134    1          0.007   A: C
  rs577773521       92185136    1          0.003   C: T
  rs1805112         92185657    1          0.468   T: C
  Chr1: 92185715    92185715    1          0.003   A: G
  Chr1: 92185881    92185881    1          0.003   G: A
  Chr1: 92195221    92195221    1          0.003   C: T
  Chr1: 92195229    92195229    1          0.003   C: T
  Chr1: 92195555    92195555    1          0.003   T: G
  rs11466584        92195652    1          0.003   T: C
  rs376528004       92200376    1          0.003   G: A
  rs2306888         92200382    1          0.11    T: C
  rs186259544       92200389    1          0.003   A: G
  rs759218481       92200513    1          0.003   A: C
  rs138007142       92200520    1          0.003   G: C
  Chr1: 92200601    92200601    1          0.003   T: G
  rs17881268        92263079    1          0.003   G: A
  rs72716444        92266656    1          0.035   A: G
  rs12123363        92266836    1          0.043   C: T
  rs189740990       101890294   1          0.003   A: G
  Chr9: 101891294   101891294   1          0.003   A: G
  rs56402414        101891447   1          0.043   G: C
  Chr9: 101891478   101891478   1          0.003   C: T
  Chr9: 101900392   101900392   1          0.003   C: G
  rs11568778        101900410   1          0.438   A: G
  rs192662552       101907072   1          0.003   T: C
  rs56251429        101907222   1          0.007   C: T
  Chr1: 218607317   218607317   1          0.003   G: A
  Chr1: 218607796   218607796   1          0.003   C: T
  rs748386982       218607817   1          0.003   G: T
  Chr1: 218607922   218607922   1          0.003   A: G
  Chr1: 218610691   218610691   1          0.003   G: T

REF -- referential allele; ALT -- alterative allele.

###### 

Detailed information of 31 tagger SNPs.

  SNP          POS         HWE    MAF     REF: ALT
  ------------ ----------- ------ ------- ----------
  rs11165377   92200634    0.11   0.07    C: T
  rs7524066    92184814    1      0.092   G: T
  rs1805113    92177938    0.73   0.10    A: G
  rs2276767    30732821    0.49   0.11    C: A
  rs2306888    92200382    1      0.11    T: C
  rs1131243    92149277    0.30   0.12    C: T
  rs1065080    67457335    1      0.19    G: A
  rs2810904    92262874    0.14   0.20    C: T
  rs1061427    67358478    0.67   0.20    G: A
  rs11165441   92224347    0.48   0.22    G: A
  rs284878     92174260    1      0.23    G: A
  rs2228048    30713842    0.81   0.25    C: T
  rs2289259    67457850    0.88   0.25    G: A
  rs2241716    41854086    0.35   0.28    C: T
  rs3738441    92224067    0.90   0.3     T: C
  rs1155705    30686414    0.62   0.33    G: A
  rs7179893    67459013    0.56   0.33    C: T
  rs2241717    41854052    0.60   0.36    C: A
  rs1750641    92178259    0.79   0.37    T: C
  rs11466512   30713126    0.49   0.38    T: A
  rs2289261    67457485    0.28   0.39    G: C
  rs1805109    92327126    0.31   0.39    C: T
  rs2038931    92174415    0.28   0.4     G: A
  rs11568753   101890227   0.73   0.41    C: T
  rs10783002   92195601    0.43   0.45    G: A
  rs1800470    41858921    1      0.46    G: A
  rs7229678    48577782    0.81   0.46    G: C
  rs1805112    92185657    1      0.46    T: C
  rs3917187    76432136    0.77   0.47    C: T
  rs2289791    67476952    0.47   0.48    G: T
  rs11165376   92200593    0.37   0.49    G: A

REF -- referential allele; ALT -- alterative allele.

###### 

General linear model for clinical variables on the occurrence of acute rejection.

  Effect                   Method               Value       F           *P* value
  ------------------------ -------------------- ----------- ----------- -----------
  Intercept                Pillai's Trace       0.72        58.52       0
  Wilks' Lambda            0.28                 58.52       0           
  Hotelling's Trace        2.53                 58.52       0           
  Roy's Largest Root       2.53                 58.52       0           
  Gender                   Pillai's Trace       0.015       0.36        0.94
  Wilks' Lambda            0.99                 0.36        0.94        
  Hotelling's Trace        0.015                0.36        0.94        
  Roy's Largest Root       0.015                0.36        0.94        
  Age                      Pillai's Trace       0.027       0.65        0.74
  Wilks' Lambda            0.97                 0.65        0.74        
  Hotelling's Trace        0.028                0.65        0.74        
  Roy's Largest Root       0.028                0.65        0.74        
  Weight                   Pillai's Trace       0.042       1.02        0.42
  Wilks' Lambda            0.96                 1.02        0.42        
  Hotelling's Trace        0.061                1.02        0.42        
  Roy's Largest Root       0.061                1.02        0.42        
  ISD                      Pillai's Trace       0.057       1.40        0.20
  Wilks' Lambda            0.97                 1.40        0.20        
  Hotelling's Trace        0.034                1.40        0.20        
  Roy's Largest Root       0.034                1.40        0.20        
  Duration                 Pillai's Trace       0.033       0.78        0.62
  Wilks' Lambda            0.97                 0.78        0.62        
  Hotelling's Trace        0.034                0.78        0.62        
  Roy's Largest Root       0.034                0.78        0.622       
  **Sir**                  **Pillai's Trace**   **0.096**   **2.44**    **0.015**
  **Wilks' Lambda**        **0.91**             **2.44**    **0.015**   
  **Hotelling's Trace**    **0.11**             **2.44**    **0.015**   
  **Roy's Largest Root**   **0.11**             **2.44**    **0.015**   
  DGF                      Pillai's Trace       0.071       1.77        0.085
  Wilks' Lambda            0.93                 1.77        0.085       
  Hotelling's Trace        0.077                1.77        0.085       
  Roy's Largest Root       0.077                1.77        0.085       

ISD -- immunosuppressive drug; Sir -- sirolimus; DGF -- delayed graft function.

###### 

Results of logistic analysis of 31 tagger SNPs in 5 model adjusted by the usage of sirolimus.

               Codominant   Dominant   Recessive   Overdominant   log-additive
  ------------ ------------ ---------- ----------- -------------- --------------
  rs1131243    0.00036      7.79E-05   0.10        0.00073        0.00011
  rs1805113    0.049        0.021      0.16        0.055          0.01
  rs1155705    0.062        0.026      0.13        0.22           0.01
  rs7524066    0.11         0.040      0.51        0.055          0.04
  rs2810904    0.24         0.15       0.18        0.43           0.09
  rs3738441    0.28         0.12       0.43        0.26           0.12
  rs1061427    0.39         0.17       0.66        0.21           0.18
  rs2276767    0.016        0.054      0.09        0.014          0.19
  rs1805112    0.085        0.79       0.04        0.065          0.33
  rs3917187    0.23         0.11       0.92        0.14           0.3
  rs7179893    0.60         0.52       0.35        0.95           0.35
  rs2241717    0.083        0.85       0.04        0.10           0.36
  rs2038931    0.61         0.54       0.34        0.89           0.36
  rs1800470    0.35         0.98       0.17        0.26           0.41
  rs11165376   0.44         0.90       0.22        0.34           0.42
  rs2289259    0.70         0.40       0.75        0.48           0.43
  rs10783002   0.14         0.68       0.09        0.08           0.49
  rs11165377   0.80         0.51       0.85        0.53           0.54
  rs11466512   0.16         0.71       0.09        0.15           0.58
  rs284878     0.89         0.77       0.65        0.93           0.68
  rs2289791    0.30         0.25       0.57        0.12           0.70
  rs11568753   0.23         0.60       0.18        0.12           0.70
  rs2289261    0.92         0.69       0.88        0.78           0.72
  rs1750641    0.93         0.79       0.74        0.98           0.72
  rs2306888    0.88         0.83       0.62        0.94           0.75
  rs11165441   0.24         0.79       0.11        0.39           0.77
  rs2228048    0.80         0.97       0.53        0.71           0.81
  rs1065080    0.50         0.56       0.40        0.34           0.83
  rs2241716    0.096        0.29       0.17        0.04           0.86
  rs7229678    0.89         0.91       0.68        0.66           0.86
  rs1805109    0.95         0.88       0.83        0.76           0.98
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AR

:   acute rejection

TGF-β

:   transforming growth factor beta

TGF-βR

:   transforming growth factor beta receptor

SNPs

:   single-nucleotide polymorphisms

TS

:   targeting sequencing

GLM

:   general linear model

MAF

:   minor allele frequency

HWE

:   Hardy-Weinberg equilibrium

LD

:   linkage disequilibrium.
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###### 

Baseline characteristics of acute rejection and stable subjects.

  Characteristics                   Stable group   AR group
  --------------------------------- -------------- -------------
  Case number                       131            69
  Age (years, mean±SD)              41.29±1.98     40.88±2.97
  Male n(%)                         82 (62.60)     42 (60.87)
  Weight(kg)                        59.45±9.12     62.69 ±8.76
  Usage of Sir n(%)                 5 (3.81)       19 (27.54)
  PRA (%) before renal transplant   0.00           0.00
  DGF(%)                            34 (25.95)     32 (46.37)

AR -- acute rejection; SD -- standard deviation; Sir -- sirolimus; PRA -- panel reactive antibody; DGF -- delayed graft function.

###### 

Results of logistic analysis of rs1131243 with the occurrence of acute rejection in 5 models adjusted by the usage of sirolimus.

  SNP         Model          Genotype               AR n (%)      non-AR n (%)   OR     Lower   Upper   *P* value
  ----------- -------------- ---------------------- ------------- -------------- ------ ------- ------- -----------
  rs1131243   Codominant     CC                     38 (55.07)    104 (79.39)                           0.00037
                             CT                     27 (39.13)    24 (18.32)     3.71   1.82    7.58    
                             TT                     4 (5.80)      3 (2.29)       5.41   1.14    25.75   
              Dominant       CC *vs*. TT+CT         38 (55.07)    27 (20.68)     3.9    1.97    7.72    7.79E-05
              Recessive      CC+CT *vs*. TT         65 (94.20)    3 (2.29)       3.57   0.77    16.54   0.11
              Overdominant   CT *vs*. CC+TT         27 (39.13)    107 (81.68)    3.31   1.65    6.65    0.00073
              Log-additive   CC *vs*. CT *vs*. TT   131 (65.50)   69 (34.50)     3.04   1.7     5.43    0.00011

Number of comparison: 5; Alpha: 0.05; Corrected Alpha: 0.01.

###### 

Association analysis of rs1131243 genotypes with Banff score (**A**) and combined Banff score (**B**).

  A                                          
  ------------ ---- ------- ---- ------- --- -------
  Borderline   27   56.25   10   55.56   1   33.33
  IA           18   37.50   4    22.22   2   66.66
  IB           1    2.08    0    0       0   0
  IIA          2    4.16    3    16.67   0   0
  IIB          0    0       1    5.56    0   0
  Sum          48   100     18   100     3   100

df=8, χ^2^=8.386, P=0.40.

  B                                                
  ------------------ ---- ------- ---- ------- --- -----
  Borderline+IA+IB   46   95.83   14   77.78   3   100
  IIA+IIB            2    4.16    4    22.22   0   0
  Sum                48   100     18   100     3   100

df=2, exact χ^2^=4.86, P=0.055.
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